En­do inks $465M bank­rupt­cy deal set­tling crim­i­nal and civ­il opi­oid cas­es

En­do agreed to pay up to $464.9 mil­lion to re­solve claims around the mar­ket­ing of its for­mer opi­oid pain med­ica­tion Opana ER.

The com­pa­ny this week an­nounced a se­ries of set­tle­ments, in­clud­ing a bank­rupt­cy agree­ment that calls for 10 an­nu­al pay­ments to the fed­er­al gov­ern­ment to­tal­ing $364.9 mil­lion. The deal al­so in­cludes an ad­di­tion­al pay­ment of up to $100 mil­lion, de­pend­ing on the “busi­ness per­for­mance of the new com­pa­ny.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER